Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: A possible surrogate marker of response?

British Journal of Haematology

Volumn 134, Issue 4, 2006, Pages 391-398

  Gerecitano, John ^a   Goy, Andre ^b   Wright, John ^c   MacGregor Cortelli, Barbara ^a   Neylon, Ellen ^a   Gonen, Mithat ^a   Esseltine, Dixie ^d   Boral, Anthony ^d   Schenkein, David ^d   Busam, Klaus ^a   Teruya Feldstein, Julie ^a   Sachs, Dana ^a,e   O'Connor, Owen A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d MILLENNIUM PHARMACEUTICALS INC   (United States)

^e UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Bortezomib; Cutaneous vasculitis; Lymphoma; Proteasome inhibitor; Rash

Indexed keywords

ANTIHISTAMINIC AGENT; BORTEZOMIB; PROTEASOME INHIBITOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG ERUPTION; ERYTHEMA; FEMALE; HUMAN; HUMAN TISSUE; LYMPHOCYTIC INFILTRATION; MACULOPAPULAR RASH; MALE; NONHODGKIN LYMPHOMA; PAPULE; PRIORITY JOURNAL; PRURITUS; PUNCH BIOPSY; SKIN BIOPSY; TREATMENT OUTCOME; VASCULITIC RASH;

AGED; BORONIC ACIDS; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; LOGISTIC MODELS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PROGNOSIS; PROTEASE INHIBITORS; PYRAZINES; SKIN; SKIN DISEASES, VASCULAR; TREATMENT OUTCOME;

EID: 33746056833     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2006.06201.x     Document Type: Article

References (19)

1. Aghajanian, C., Soignet, S., Dizon, D.S., Pien, C.S., Adams, J., Elliott, P.J., Sabbatini, P., Miller, V., Hensley, M.L., Pezzulli, S., Canales, C., Daud, A. & Spriggs, D.R. (2002) A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clinical Cancer Research, 8, 2505-2511.
2. Agterof, M.J. & Biesma, D.H. (2005) Images in clinical medicine. Bortezomib-induced skin lesions. New England Journal of Medicine, 352, 2534.
3. Cheson, B.D., Horning, S.J., Coiffier, B., Shipp, M.A., Fisher, R.I., Connors, J.M., Lister, T.A., Vose, J., Grillo-Lopez, A., Hagenbeek, A., Cabanillas, F., Klippensten, D., Hiddemann, W., Castellino, R., Harris, N.L., Armitage, J.O., Carter, W., Hoppe, R. & Canellos, G.P. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. Journal of Clinical Oncology, 17, 1244.
4. Cohen, E.E., Rosen, F., Stadler, W.M., Recant, W., Stenson, K., Huo, D. & Vokes, E.E. (2003) Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. Journal of Clinical Oncology, 21, 1980-1987.
5. Goy, A., Bernstein, S., Kahl, B., Epner, E., Leonard, J.P., Stadtmauer, E., Morgan, E., Belt, R., Baidas, S. & Fischer, R. (2005a) Bortezomib in patients with relapsed or refractory mantle cell lymphoma (MCL): preliminary results of the PINNACLE study. 2005 ASCO Annual Meeting, Abstract no. 6563. Available at: http://www.asco.org.
6. Goy, A., Younes, A., McLaughlin, P., Pro, B., Romaguera, J.E., Hagemeister, F., Fayad, L., Dang, N.H., Samaniego, F., Wang, M., Broglio, K., Samuels, B., Gilles, F., Sarris, A.H., Hart, S., Trehu, E., Schenkein, D., Cabanillas, F. & Rodriguez, A.M. (2005b) Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-Cell non-Hodgkin's lymphoma. Journal of Clinical Oncology, 23, 667-675.
7. Langford, C.A. (2003) 15. Vasculitis. Journal of Allergy and Clinical Immunology, 111, S602-S612.
8. Merkel, P.A. (2001) Drug-induced vasculitis. Rheumatic Diseases Clinics of North America, 27, 849-862.
9. Min, C.K., Lee, S., Kim, Y.J., Eom, K.S., Lee, J.W., Min, W.S., Kim, C.C., Cho, C.S. & Park, G. (2006) Cutaneous leucoclastic vasculitis (LV) following bortezomib therapy in a myeloma patient; association with pro-inflammatory cytokines. European Journal of Haematology, 76, 265-268.
10. O'Connor, O.A., Wright, J., Moskowitz, C., Muzzy, J., MacGregor-Cortelli, B., Stubblefield, M., Straus, D., Portlock, C., Hamlin, P., Choi, E., Dumetrescu, O., Qin, J., Esseltine, D., Trehu, E., Adams, J., Schenkein, D. & Zelenetz, A. (2005a) Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. Journal of Clinical Oncology, 23, 676-684.
11. O'Connor, O.A., Wright, J., Moskowitz, C., Straus, D., Portlock, C., Hamlin, P., Neylon, E., Evans, A., Winter, J., Gordon, L., Koc, O., Horvath, N., Blumel, S., Vose, J., Schenkein, D. & Zelenetz, A. (2005b) Targeting the proteasome pathway with bortezomib in patients with mantle cell (MCL) and follicular lymphoma (FL) produces prolonged progression free survival among responding patients: results of a multicenter phase II experience. Annals of Oncology, 16, Abstract no. 99.
12. Orlowski, R.Z. & Baldwin, Jr, A.S. (2002) NF-kappaB as a therapeutic target in cancer. Trends in Molecular Medicine, 8, 385-389.
13. Orlowski, R.Z., Stinchcombe, T.E., Mitchell, B.S., Shea, T.C., Baldwin, A.S., Stahl, S., Adams, J., Esseltine, D.L., Elliott, P.J., Pien, C.S., Guerciolini, R., Anderson, J.K., Depcik-Smith, N.D., Bhagat, R., Lehman, M.J., Novick, S.C., O'Connor, O.A. & Soignet, S.L. (2002) Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. Journal of Clinical Oncology, 20, 4420-4427.
14. Perez-Soler, R. & Saltz, L. (2005) Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? Journal of Clinical Oncology, 23, 5235-5246.
15. Perez-Soler, R., Chachoua, A., Hammond, L.A., Rowinsky, E.K., Huberman, M., Karp, D., Rigas, J., Clark, G.M., Santabarbara, P. & Bonomi, P. (2004) Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. Journal of Clinical Oncology, 22, 3238-3247.
16. Richardson, P.G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S.V., Srkalovic, G., Alsina, M., Alexanian, R., Siegel, D., Orlowski, R.Z., Kuter, D., Limentani, S.A., Lee, S., Hideshima, T., Esseltine, D.L., Kauffman, M., Adams, J., Schenkein, D.P. & Anderson, K.C. (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. New England Journal of Medicine, 348, 2609-2617.
17. Richardson, P.G., Sonneveld, P., Schuster, M.W., Irwin, D., Stadtmauer, E.A., Facon, T., Harousseau, J.L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., Reece, D., San-Miguel, J.F., Blade, J., Boccadoro, M., Cavenagh, J., Dalton, W.S., Boral, A.L., Esseltine, D.L., Porter, J.B., Schenkein, D. & Anderson, K.C. (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. New England Journal of Medicine, 352, 2487-2498.
18. Saltz, L., Kies, M., Abbruzzese, J., Azarnia, M. & Needle, M. (2003) The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies. Proceedings of the American Society of Clinical Oncology, 22, 204.
19. Soulieres, D., Senzer, N.N., Vokes, E.E., Hidalgo, M., Agarwala, S.S. & Siu, L.L. (2004) Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. Journal of Clinical Oncology, 22, 77-85.